$1.36B in CY2024 Part D spend218K claims · 38K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Tofacitinib used for?
XELJANZ (tablets and oral solution) and XELJANZ XR (extended-release tablets) are Janus kinase (JAK) inhibitors.
Is there a generic for Tofacitinib?
Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.
How much does my plan pay for Tofacitinib?
Across 329 Part D plans, Tofacitinib averages $128.36/unit (NADAC). Lowest available: $73.83/unit. Highest in distribution: $207.71/unit.
Is Tofacitinib on the FDA shortage list?
No. Tofacitinib is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (7 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.